Bronchioloalveolar carcinoma: The case for two diseases

Clinical Lung Cancer

Volumn 9, Issue 1, 2008, Pages 24-29

  Garfield, David H ^a   Cadranel, Jacques ^b   West, Howard L ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c SWEDISH MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Histologic subtype; K ras; Mucinous; Non small cell lung cancer; Nonmucinous

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL;

CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; METAPLASIA; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; RADIODENSITOMETRY; REVIEW; TREATMENT RESPONSE;

EID: 39149116361     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.004     Document Type: Review

References (79)

1. Malassez L. Examen histologique d'un cas de cancer enchephaloide du poumon (epithelioma). Arch Physiol Norm Pathol 1876; 3:353-72.
2. Liebow AA. Bronchiolo-alveolar carcinoma. Adv Intern Med 1960; 10:329-58.
3. Storey CF, Knudson KP, Lawrence BJ. Bronchiolar ("Alveolar Cell") carcinoma of the lung. J Thorac Surg 1953; 26:331-406.
4. Travis WD, Brambilla E, Müller-Hermelink HK, et al. (Eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon; 2004.
5. Manning JT, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma. Cancer 1984; 54:525-34.
6. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000; 53:537-40.
7. Flieder DB. Screen-detected adenocarcinomas of the lung: practical points for surgical pathologists. Am J Clin Pathol 2003; 119(suppl 1):S39-S57.
8. Franklin WA, Chanin T, Gonzalez A. Molecular and cellular pathology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, et al, eds. Lung Cancer: Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Williams; 2005:245-8.
9. Clayton F. Bronchioloalveolar carcinoma. Cancer 1986; 57:1555-64.
10. Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu 1988; 23:361-94.
11. Elson CE, Moore SP, Johnston WW. Morphologic and immunocytochemical studies of bronchioloalveolar carcinoma at Duke University Medical Center, 1968-1986. Anal Quant Cytol Histol 1989; 11:261-74.
12. MacDonald LL, Yazdi HN. Fine-needle aspiration biopsy of bronchioloalveolar carcinoma. Cancer 2001; 93:29-34.
13. Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002; 15:538-42.
14. Sarantopoulos GP, Gui D, Shintaku P, et al. Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation. Arch Pathol Lab Med 2004; 128:406-14.
15. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol 2001; 116:319-25.
16. Matson VJ, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary lung tumors: correlation with histological type and grade. Histopathology 2004; 45:125-34.
17. Simsir A, Wei X-J, Yee H, et al. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma. Am J Clin Pathol 2004; 121:350-7.
18. Saad RS, Cho P, Silverman JF, et al. Usefulness of cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol 2004; 122:421-7.
19. Shah RN, Badve S, Papreddy K, et al. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. Hum Pathol 2002; 33:915-20.
20. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung. Am J Surg Pathol 2004; 28:442-52.
21. Tsuta K, Ishii G, Nitadori J, et al. Comparison of the immunophenotypes of signet-ring cell caracinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 2006; 209:78-87.
22. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29:633-9.
23. Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001; 14:72-84.
24. Lopez JI, Colby TV, Gazdar AF. Current status of small peripheral adenocarcinomas of the lung and their importance to pathologists. Ann Diagn Pathol 2005; 9:115-22.
25. Morandi L, Asioli S, Cavazza A, et al. Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung. Lung Cancer 2007; 56:35-42.
26. Aoyagi Y, Yokose T, Minami Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001; 61:7950-4.
27. Lantuejoul S, Nicholson AG, Sartori G, et al. Mucinous cells in type I pulmonary congenital cystic adenomatoid malformations as mucinous bronchioloalveolar carcinoma precursors. Am J Surg Pathol 2007; 31:961-9.
28. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1996; 75:2844-52.
29. Maeshima A, Sakamoto M, Hirohashi. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung immunohistochemical examination and K-ras gene mutation. Virchows Arch 2002; 440:598-603.
30. Nakajima T, Kodama T, Tsumuraya M, et al. S-100 protein-positive Langerhans cells in various human lung cancers, especially in peripheral adenocarcinomas. Virchows Arch [Pathol Anat] 1985; 407:177-89.
31. Axiotis CA, Jennings TA. Observations on bronchiolo-alveolar carcinomas with special emphasis on localized lesions. Am J Surg Pathol 1988; 12:918-31.
32. Tosi P, Sforza V, Santopietro R, et al. Bronchiolo-alveolar carcinoma: an analysis of survival predictors. Eur J Cancer 1992; 28A:1365-70.
33. Bellocq A, Antoine M, Flahault A, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma. Am J Pathol 1998; 152:83-92.
34. Wislez M, Massiani M-A, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest 2003; 123:1868-77.
35. Regnard JF, Santelmo N, Romdham N, et al. Bronchioloalveolar lung carcinoma; results of surgical treatment and prognostic factors. Chest 1998; 114:45-50.
36. Albertine KH, Steiner RM, Radack DM, et al. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioloalveolar cell carcinoma. Chest 1998; 113:997-1006.
37. Volpino P, D'Andrea N, Cangemi R, et al. Bronchioloalveolar carcinoma: clinical, radiographic, and pathological findings. J Cardiovasc Surg 2001; 42:261-7.
38. Shah RM, Balsara G, Webster M, et al. Bronchioloalveolar cell carcinoma. Impact of histology on dominant CT pattern. J Thorac Imaging 2000; 15:180-6.
39. Okubo K, Mark EJ, Flieder D, et al. Bronchioloalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. J Thorac Cardiovasc Surg 1999; 118:702-9.
40. Gaeta M, Blandino A, Pergolizzi S, et al. Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. Lung Cancer 2003; 42:319-26.
41. Mihara N, Ichicado K, Johkoh T, et al. The subtypes of localized bronchioloalveolar carcinoma: CT-pathologic correlation in 18 cases. AJR 1999; 173:75-9.
42. Im J-G, Han MC, Yu EJ, et al. Lobar bronchioloalveolar carcinoma: "Angiogram Sign" on CT scans. Radiology 1990; 176:749-53.
43. Tachibana K, Nakagawa K, Endo M, et al. Differences in high-resolution computed tomography (HRCT) findings between mucinous and non-mucinous bronchioloalveolar carcinoma (BAC) less than 3cm. Presented at the 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007. J Thorac Oncol 2007; 2(suppl 4):S419-20.
44. Kim B-T, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR 1998; 170:935-9.
45. Sung YM, Lee KS, Kim B-T, et al. Lobar mucinous bronchioloalveolar carcinoma of the lung showing negative FDG uptake on integrated PET/CT Eur Radiol 2005; 15:2075-8.
46. Yap CS, Schiepers C, Fishbein MC, et al. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med 2002; 29:1166-73.
47. Gaeta M, Blandino A, Scribano E, et al. Magnetic resonance imaging of bronchioloalveolar carcinoma. J Thorac Imaging 2000; 15:41-7.
48. Gaeta M, Minutoli F, Ascenti G, et al. MR white lung sign: incidence and significance in pulmonary consolidations. J Comput Assist Tomogr 2001; 25:890-6.
49. Guedj N, Couvelard A, Arcangeli G, et al. Angiogenesis and extracellular matrix remodeling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumors. Histopathology 2004; 44:251-6.
50. Ohori NP, Yousem SA, Griffin J, et al. Comparison of extracellular matrix antigens in subtypes of bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Am J Surg Pathol 1992; 16:675-86.
51. Ohori NP, Coppola D, Landreneau RJ. CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Mod Pathol 1996; 9:507-12.
52. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implication on pharmacologic treatment. J Clin Oncol 2005; 23:857-65.
53. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12:1647-53.
54. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9:320-69.
55. Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinoma. Am J Clin Pathol 2007; 128:100-8.
56. Wislez M, Antoine M, Poulot V, et al. IFCT0401-bio trial: predictive biological markers for disease control (DC) of patients with non-resectable, adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib. J Clin Oncol 2007; 25(18 suppl):422s (Abstract 7653).
57. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes. J Clin Oncol 2005; 23:6838-45.
58. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97:339-46.
59. Erman M, Grunenwald D, Penault-Llorca F, et al. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 2005; 47:315-23.
60. Furák J, Troján I, Szoke T, et al. Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival. Eur J Cardiothorac Surg 2003; 23:818-23.
61. Marchetti A, Pellegrini S, Bertacca G, et al. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. J Pathol 1998; 184:240-6.
62. Nuorva K, Soini Y, Kamel D, et al. p53 protein accumulation and the presence of human papillomarvirus DNA in bronchiolo-alveolar carcinoma correlate with poor prognosis. Int J Cancer 1995; 64:424-9.
63. McDonald JW, Pilgram TK. Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma. Histopathology 1999; 34:439-46.
64. Nakanishi K, Kawai T, Kumaki F, et al. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 2003; 120:712-19.
65. Saad RS, Liu Y, Han H, et al. Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Mod Pathol 2004; 17:1235-42.
66. Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 2007; 55:115-21.
67. Ghazizadeh M, Jin E, Shimizu H, et al. Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinoma. Respiration 2005; 72:68-73.
68. West HL, Crowley JJ, Vance RB, et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group Study. Ann Oncol 2005; 16:1076-80.
69. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
70. Manning JT, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: the significance of two histopathological types. Cancer 1984; 54:525-34.
71. Daly RC, Trastek VF, Pairolero PC, et al. Bronchioloalveolar carcinomas: factors affecting survival. Ann Thorac Surg 1991; 51:368-77.
72. Dunn D, Hertel B, Norwood W, et al. Bronchioloalveolar carcinoma of the lung: a clinicopathological study. Ann Thorac Surg 1978; 26:241-9.
73. Dumont P, Gasser B, Rouge C, et al. Bronchioloalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998; 113:391-5.
74. De Leyn P, Vaansteenkiste F, Sciot R, et al. Bronchioloalveolar carcinoma: long-term survival of 23 resected patients. Acta Chir Belg 1995; 95:220-2.
75. Ebright MI, Zakowski M, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002; 74:1640-7.
76. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004; 78:1728-33.
77. Carretta A, Canneto B, Calori G, et al. Evaluation of radiological and pathological prognostic factors in surgically-treated patients with bronchioloalveolar carcinoma. Eur J Cardiothorac Surg 2001; 20:367-71.
78. Zell JA, Ou SH, Ziogas A, et al. Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol 2006; 17:1255-62.
79. Garfield DH, Cadranel JL, Wislez M, et al. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol 2006; 1:344-59.